Fluvoxamine: A selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder

Bernardo Dell'Osso, Andrea Allen, Eric Hollander

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Fluvoxamine is the selective serotonin re-uptake inhibitor with the largest database in the treatment of obsessive-compulsive disorder, a severe, and often chronic, anxiety disorder associated with substantial impairment in functioning. The selective serotonin re-uptake inhibitors represent a first-line treatment in patients with obsessive-compulsive disorder. These agents work primarily by blocking the re-uptake of serotonin into the presynaptic nerve terminal, which is believed to be mediated by their effects on the serotonin transport system. In the last two decades, the anti-obsessional effect of fluvoxamine has been tested in several double-blind, placebo-controlled and active-comparison studies, demonstrating its superior efficacy over obsessions and compulsions compared with non-serotonergic antidepressants (i.e., desipramine) and equal efficacy to clomipramine (a tricyclic antidepressant with potent serotonin re-uptake inhibition) and other selective serotonin re-uptake inhibitors (paroxetine and citalopram). However, compared with clomipramine, the selective serotonin re-uptake inhibitor fluvoxamine showed fewer side effects and better tolerability. This reflects the poor affinity of this compound for adrenergic, muscarinic, cholinergic or histaminergic receptors.

Original languageEnglish (US)
Pages (from-to)2727-2740
Number of pages14
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number15
DOIs
StatePublished - Dec 2005
Externally publishedYes

Fingerprint

Fluvoxamine
Obsessive-Compulsive Disorder
Serotonin Uptake Inhibitors
Clomipramine
Serotonin
Cholinergic Agents
Obsessive Behavior
Paroxetine
Citalopram
Desipramine
Tricyclic Antidepressive Agents
Presynaptic Terminals
Therapeutics
Anxiety Disorders
Adrenergic Agents
Antidepressive Agents
Placebos
Databases

Keywords

  • Fluvoxamine
  • Obsessive-compulsive disorder
  • Selective serotonin re-uptake inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Fluvoxamine : A selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. / Dell'Osso, Bernardo; Allen, Andrea; Hollander, Eric.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 15, 12.2005, p. 2727-2740.

Research output: Contribution to journalArticle

@article{01b19e0f906345e594949c06ac2b1338,
title = "Fluvoxamine: A selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder",
abstract = "Fluvoxamine is the selective serotonin re-uptake inhibitor with the largest database in the treatment of obsessive-compulsive disorder, a severe, and often chronic, anxiety disorder associated with substantial impairment in functioning. The selective serotonin re-uptake inhibitors represent a first-line treatment in patients with obsessive-compulsive disorder. These agents work primarily by blocking the re-uptake of serotonin into the presynaptic nerve terminal, which is believed to be mediated by their effects on the serotonin transport system. In the last two decades, the anti-obsessional effect of fluvoxamine has been tested in several double-blind, placebo-controlled and active-comparison studies, demonstrating its superior efficacy over obsessions and compulsions compared with non-serotonergic antidepressants (i.e., desipramine) and equal efficacy to clomipramine (a tricyclic antidepressant with potent serotonin re-uptake inhibition) and other selective serotonin re-uptake inhibitors (paroxetine and citalopram). However, compared with clomipramine, the selective serotonin re-uptake inhibitor fluvoxamine showed fewer side effects and better tolerability. This reflects the poor affinity of this compound for adrenergic, muscarinic, cholinergic or histaminergic receptors.",
keywords = "Fluvoxamine, Obsessive-compulsive disorder, Selective serotonin re-uptake inhibitors",
author = "Bernardo Dell'Osso and Andrea Allen and Eric Hollander",
year = "2005",
month = "12",
doi = "10.1517/14656566.6.15.2727",
language = "English (US)",
volume = "6",
pages = "2727--2740",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "15",

}

TY - JOUR

T1 - Fluvoxamine

T2 - A selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder

AU - Dell'Osso, Bernardo

AU - Allen, Andrea

AU - Hollander, Eric

PY - 2005/12

Y1 - 2005/12

N2 - Fluvoxamine is the selective serotonin re-uptake inhibitor with the largest database in the treatment of obsessive-compulsive disorder, a severe, and often chronic, anxiety disorder associated with substantial impairment in functioning. The selective serotonin re-uptake inhibitors represent a first-line treatment in patients with obsessive-compulsive disorder. These agents work primarily by blocking the re-uptake of serotonin into the presynaptic nerve terminal, which is believed to be mediated by their effects on the serotonin transport system. In the last two decades, the anti-obsessional effect of fluvoxamine has been tested in several double-blind, placebo-controlled and active-comparison studies, demonstrating its superior efficacy over obsessions and compulsions compared with non-serotonergic antidepressants (i.e., desipramine) and equal efficacy to clomipramine (a tricyclic antidepressant with potent serotonin re-uptake inhibition) and other selective serotonin re-uptake inhibitors (paroxetine and citalopram). However, compared with clomipramine, the selective serotonin re-uptake inhibitor fluvoxamine showed fewer side effects and better tolerability. This reflects the poor affinity of this compound for adrenergic, muscarinic, cholinergic or histaminergic receptors.

AB - Fluvoxamine is the selective serotonin re-uptake inhibitor with the largest database in the treatment of obsessive-compulsive disorder, a severe, and often chronic, anxiety disorder associated with substantial impairment in functioning. The selective serotonin re-uptake inhibitors represent a first-line treatment in patients with obsessive-compulsive disorder. These agents work primarily by blocking the re-uptake of serotonin into the presynaptic nerve terminal, which is believed to be mediated by their effects on the serotonin transport system. In the last two decades, the anti-obsessional effect of fluvoxamine has been tested in several double-blind, placebo-controlled and active-comparison studies, demonstrating its superior efficacy over obsessions and compulsions compared with non-serotonergic antidepressants (i.e., desipramine) and equal efficacy to clomipramine (a tricyclic antidepressant with potent serotonin re-uptake inhibition) and other selective serotonin re-uptake inhibitors (paroxetine and citalopram). However, compared with clomipramine, the selective serotonin re-uptake inhibitor fluvoxamine showed fewer side effects and better tolerability. This reflects the poor affinity of this compound for adrenergic, muscarinic, cholinergic or histaminergic receptors.

KW - Fluvoxamine

KW - Obsessive-compulsive disorder

KW - Selective serotonin re-uptake inhibitors

UR - http://www.scopus.com/inward/record.url?scp=29244465500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=29244465500&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.15.2727

DO - 10.1517/14656566.6.15.2727

M3 - Article

C2 - 16316311

AN - SCOPUS:29244465500

VL - 6

SP - 2727

EP - 2740

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -